MedTrace Logo

Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly

NCT00136929 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2005-12-13

No results posted yet for this study

Summary

This is a prospective, randomized, multi-center, international trial comparing two reperfusion strategies in elderly (age \>= 70 years) patients with acute myocardial infarction: primary percutaneous coronary intervention (PCI) versus intravenous thrombolytic therapy. Clinical endpoints will be collected in the hospital, at 1 month, 6 months, and 1 year post-randomization. The primary endpoint is 30 day death or disabling stroke. The study null hypothesis is that there will be no significant difference in death or disabling stroke at 30 days post-randomization between patients treated with PCI versus thrombolytics.

Conditions

Interventions

DRUG

Thrombolytic therapy

PROCEDURE

Percutaneous coronary intervention (PCI)

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Guidant Corporation

    collaborator INDUSTRY

  • PAMI Coordinating Center

    lead OTHER

Principal Investigators

  • Felix Zijlstra, M.D. · Ziekenhuis de Weezenlanden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00136929 on ClinicalTrials.gov